PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer
出版年份 2019 全文链接
标题
PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 20, Issue 7, Pages 1631
出版商
MDPI AG
发表日期
2019-04-03
DOI
10.3390/ijms20071631
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Programmed death-ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer
- (2018) Masahiko Amatatsu et al. CANCER SCIENCE
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- (2018) Thomas Powles et al. LANCET
- High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
- (2018) Carsten Krieg et al. NATURE MEDICINE
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018
- (2018) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- (2018) Ezra E W Cohen et al. LANCET
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
- (2017) Leora Horn et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
- (2017) Joshua Bauml et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma
- (2017) Kazuki Takada et al. LUNG CANCER
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Expression and clinical significance of programmed death‑1 on lymphocytes and programmed death ligand‑1 on monocytes in the peripheral blood of patients with cervical cancer
- (2017) Ying Zhang et al. Oncology Letters
- Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients
- (2017) Oscar Arrieta et al. Oncotarget
- PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity
- (2017) Maria Gato-Cañas et al. Cell Reports
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- (2016) Antoni Ribas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
- (2016) Sarah B Goldberg et al. LANCET ONCOLOGY
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- A core of kinase-regulated interactomes defines the neoplastic MDSC lineage
- (2015) Maria Gato-Cañas et al. Oncotarget
- Characterization of thein vivoimmune network of IDO, tryptophan metabolism, PD-L1, andCTLA-4in circulating immune cells in melanoma
- (2015) I Chevolet et al. OncoImmunology
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy
- (2012) Katarzyna Karwacz et al. OncoImmunology
- PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+T cells
- (2011) Katarzyna Karwacz et al. EMBO Molecular Medicine
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Targeting dendritic cell signaling to regulate the response to immunization
- (2008) D. Escors et al. BLOOD
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started